menu
    • menu
    [{"orgOrder":0,"company":"Stalicla","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Mavoglurant","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0.27000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.27000000000000002,"dosageForm":"Tablet","sponsorNew":"Stalicla \/ Novartis","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ Novartis"},{"orgOrder":0,"company":"Stalicla","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Mavoglurant","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stalicla \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Stalicla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mavoglurant","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stalicla \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Mavoglurant

    Menu

    Mavoglurant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Stalicla

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Stalicla

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mavoglurant

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            STALICLA Starts Phase 3 DDI Study of STP7 to Treat Cocaine Use Disorder in the U.S.

                            Details : STP7 (Mavoglurant) is the most clinically advanced negative allosteric modulator of the glutamate receptor 5 (mGluR5 NAM). It is being evaluated for the treatment of cocaine use disorder.

                            Brand Name : STP7

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 02, 2024

                            Lead Product(s) : Mavoglurant

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Stalicla

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Stalicla

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mavoglurant

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Stalicla Signs Cooperative Research And Development Agreement (CRADA) With Us National Institute On Drug Abuse...

                            Details : The agreement covers the clinical development program of STP7 (mavoglurant) to treat patients diagnosed with cocaine use disorder (CUD), including a Phase 3 study.

                            Brand Name : STP7

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 08, 2023

                            Lead Product(s) : Mavoglurant

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Stalicla

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Stalicla

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mavoglurant

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $270.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Stalicla Signs Exclusive In-Licensing Agreement for Late-Stage Clinical Neuropsychiatric and Neurodevelopmenta...

                            Details : Under the terms of the agreement, STALICLA has acquired worldwide rights to AFQ056 (mavoglurant) for substance-use disorders, neurodevelopmental disorders, and other indications. Mavoglurant is a selective non allosteric metabotropic glutamate receptor 5...

                            Brand Name : AFQ056

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 09, 2023

                            Lead Product(s) : Mavoglurant

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $270.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth